Tighter FDA Review Squeezing Device VCs
For over three decades, medical device investors have accepted the Food and Drug Administration's crucial role as traffic cop for their start-ups. Yes, the agency could be tough, but a green light opened a lucrative road for device companies. But venture capitalists are increasingly worried that tighter controls on regulation could endanger innovation.
You may also be interested in...
OrbiMed Closes $550 Million Fund
OrbiMed Advisers just closed a $550 million fund, a tick more than its previous general fund and raised mostly from previous backers. OrbiMed’s general partners say they’ll make no radical departures from their previous formula despite the upheaval brought on by the recession and the federal health care reform saga.
Device Prom Song: Looks Like We Made It
A year ago, things looked bleak everywhere, including devices. But investors and executives battened down the hatches, tightened their belts, and adopted every other conceivable austerity-tied cliché. Things now are beginning to look up…a little.
Following the Money in Medical Devices
Venture capitalists might cry poor, but, in fact, many leading firms have raised new funds over the past year, pooling more than $1.5 billion for medical device investments. The only question facing entrepreneurs and executives is: are they buying what you’re selling?